Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study (Q77668015)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference

1 reference

1 reference

T Klingebiel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

P Bader

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

R Bares

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

J Beck

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

B Hero

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

H Jürgens

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

P Lang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

D Niethammer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

B Rath

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

R Handgretinger

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 August 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

1398-1402

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

The treatment of advanced neuroblastoma. Results of the spanish neuroblastoma study group (SNSG) studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

[131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Autologous transplantation with peripheral blood stem cells in children and young adults after myeloablative treatment: nonrandomized comparison between GM-CSF and G-CSF for mobilization

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

First experience with prognostic factors in unselected neuroblastoma patients. The Austrian neuroblastoma 87 study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Neuroblastoma: dose-related sensitivity of MIBG scanning in detection

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900130-0

7 January 2021

10.1016/S0959-8049(98)00130-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9849423%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference